export interface DrugSynergyEntry {
  id: number;
  paper: string;
  dataset: string;
  synergyMetric: string;
  model: string;
  evaluationStrategy: string;
  regressionResults: string;
  additionalInfo: string;
}

export const drugSynergyData: DrugSynergyEntry[] = [
  { id: 1, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Leave combination out - 5-fold CV", regressionResults: "MSE=255.49, RMSE=15.91±1.56, Pearson=0.73±0.04", additionalInfo: "Table 2" },
  { id: 2, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Gradient Boosting", evaluationStrategy: "Leave combination out - 5-fold CV", regressionResults: "MSE=275.39, RMSE=16.54±1.37, Pearson=0.69±0.02", additionalInfo: "Table 2" },
  { id: 3, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Random Forest", evaluationStrategy: "Leave combination out - 5-fold CV", regressionResults: "MSE=307.56, RMSE=17.49±1.63, Pearson=0.65±0.03", additionalInfo: "Table 2" },
  { id: 4, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "SVM", evaluationStrategy: "Leave combination out - 5-fold CV", regressionResults: "MSE=398.39, RMSE=19.92±1.28, Pearson=0.50±0.03", additionalInfo: "Table 2" },
  { id: 5, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Elastic Net", evaluationStrategy: "Leave combination out - 5-fold CV", regressionResults: "MSE=420.24, RMSE=20.46±1.29, Pearson=0.44±0.03", additionalInfo: "Table 2" },
  { id: 6, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Baseline (Median Polish)", evaluationStrategy: "Leave combination out - 5-fold CV", regressionResults: "MSE=477.77, RMSE=21.80±1.49, Pearson=0.43±0.02", additionalInfo: "Table 2" },
  { id: 7, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Leave one drug out - 5-fold CV", regressionResults: "MSE=413.51, RMSE=19.41±5.72, Pearson=0.51±0.09", additionalInfo: "Supplementary Table S8" },
  { id: 8, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Gradient Boosting", evaluationStrategy: "Leave one drug out - 5-fold CV", regressionResults: "MSE=435.92, RMSE=19.90±5.60, Pearson=0.48±0.08", additionalInfo: "Supplementary Table S8" },
  { id: 9, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Random Forest", evaluationStrategy: "Leave one drug out - 5-fold CV", regressionResults: "MSE=443.93, RMSE=20.21±5.64, Pearson=0.47±0.10", additionalInfo: "Supplementary Table S8" },
  { id: 10, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "SVM", evaluationStrategy: "Leave one drug out - 5-fold CV", regressionResults: "MSE=459.87, RMSE=20.54±5.52, Pearson=0.39±0.08", additionalInfo: "Supplementary Table S8" },
  { id: 11, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Elastic Net", evaluationStrategy: "Leave one drug out - 5-fold CV", regressionResults: "MSE=476.42, RMSE=20.83±5.77, Pearson=0.35±0.08", additionalInfo: "Supplementary Table S8" },
  { id: 12, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Baseline (Median Polish)", evaluationStrategy: "Leave one drug out - 5-fold CV", regressionResults: "MSE=499.23, RMSE=21.29±5.95, Pearson=0.34±0.08", additionalInfo: "Supplementary Table S8" },
  { id: 13, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Leave cell line out - novel cell lines", regressionResults: "MSE=386.90, RMSE=18.18±7.52, Pearson=0.59±0.14", additionalInfo: "Supplementary Table S9" },
  { id: 14, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Gradient Boosting", evaluationStrategy: "Leave cell line out - novel cell lines", regressionResults: "MSE=405.40, RMSE=18.74±7.37, Pearson=0.57±0.14", additionalInfo: "Supplementary Table S9" },
  { id: 15, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Random Forest", evaluationStrategy: "Leave cell line out - novel cell lines", regressionResults: "MSE=407.44, RMSE=18.79±7.38, Pearson=0.57±0.13", additionalInfo: "Supplementary Table S9" },
  { id: 16, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "SVM", evaluationStrategy: "Leave cell line out - novel cell lines", regressionResults: "MSE=422.71, RMSE=19.17±7.42, Pearson=0.50±0.13", additionalInfo: "Supplementary Table S9" },
  { id: 17, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Elastic Net", evaluationStrategy: "Leave cell line out - novel cell lines", regressionResults: "MSE=435.57, RMSE=19.51±7.41, Pearson=0.48±0.13", additionalInfo: "Supplementary Table S9" },
  { id: 18, paper: "DeepSynergy (2018)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Baseline (Median Polish)", evaluationStrategy: "Leave cell line out - novel cell lines", regressionResults: "MSE=460.69, RMSE=20.18±7.29, Pearson=0.47±0.13", additionalInfo: "Supplementary Table S9" },
  { id: 19, paper: "AuDNNsynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "AuDNNsynergy (93,019 features)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "Rank Correlation=0.73±0.02, MSE=241.12±43.52, RMSE=15.46±1.44, Pearson=0.74±0.03", additionalInfo: "Table 2" },
  { id: 20, paper: "AuDNNsynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "DeepSynergy (8,846 features)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "Rank Correlation=0.66±0.02, MSE=255.49±49.54, RMSE=15.91±1.56, Pearson=0.73±0.04", additionalInfo: "Table 2" },
  { id: 21, paper: "AuDNNsynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Gradient Boosting (93,019 features)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "Rank Correlation=0.64±0.02, MSE=310.73±50.40, RMSE=17.57±1.42, Pearson=0.64±0.02", additionalInfo: "Table 2" },
  { id: 22, paper: "AuDNNsynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Gradient Boosting (8,846 features)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "Rank Correlation=0.64±0.01, MSE=308.06±49.34, RMSE=17.50±1.39, Pearson=0.64±0.02", additionalInfo: "Table 2" },
  { id: 23, paper: "AuDNNsynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Random Forest (93,019 features)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "Rank Correlation=0.64±0.02, MSE=326.31±53.54, RMSE=18.00±1.45, Pearson=0.63±0.02", additionalInfo: "Table 2" },
  { id: 24, paper: "AuDNNsynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Random Forest (8,846 features)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "Rank Correlation=0.63±0.02, MSE=330.18±51.45, RMSE=18.12±1.37, Pearson=0.61±0.03", additionalInfo: "Table 2" },
  { id: 25, paper: "AuDNNsynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Elastic Net (93,019 features)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "Rank Correlation=0.49±0.02, MSE=422.72±54.35, RMSE=20.52±1.30, Pearson=0.44±0.02", additionalInfo: "Table 2" },
  { id: 26, paper: "AuDNNsynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Elastic Net (8,846 features)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "Rank Correlation=0.49±0.02, MSE=424.38±54.39, RMSE=20.56±1.30, Pearson=0.44±0.02", additionalInfo: "Table 2" },
  { id: 27, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "TranSynergy (Gene dep + Gene exp)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=231±21, Spearman=0.730±0.016, Pearson=0.746±0.018", additionalInfo: "Network propagated targets with PPI - Table 5" },
  { id: 28, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "TranSynergy (Gene dependency)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=232±21, Spearman=0.725±0.016, Pearson=0.746±0.017", additionalInfo: "Network propagated targets with PPI - Table 5" },
  { id: 29, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "TranSynergy (Gene expression)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=241±19, Spearman=0.721±0.021, Pearson=0.741±0.025", additionalInfo: "Network propagated targets with PPI - Table 5" },
  { id: 30, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "TranSynergy (No cell line features)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=390±11, Spearman=0.505±0.007, Pearson=0.400±0.012", additionalInfo: "Network propagated targets with PPI - Table 5" },
  { id: 31, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "TranSynergy (Observed targets)", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=300±31, Spearman=0.645±0.036, Pearson=0.634±0.038", additionalInfo: "No network propagation - Table 1 & Table 5" },
  { id: 32, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=243±17, Spearman=0.698±0.016, Pearson=0.726±0.015", additionalInfo: "No network propagation - Table 1 & Table 5" },
  { id: 33, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "TranSynergy", evaluationStrategy: "Leave cell line out (4 clusters, holdout test)", regressionResults: "Spearman=0.552±0.013, Pearson=0.513±0.019", additionalInfo: "Table 3" },
  { id: 34, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Leave cell line out (4 clusters, holdout test)", regressionResults: "Spearman=0.547±0.010, Pearson=0.501±0.010", additionalInfo: "Table 3" },
  { id: 35, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "TranSynergy", evaluationStrategy: "Leave drug out (5 clusters, holdout test)", regressionResults: "Spearman=0.477±0.040, Pearson=0.457±0.031", additionalInfo: "Table 3" },
  { id: 36, paper: "TranSynergy (2021)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 18,553 samples used", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Leave drug out (5 clusters, holdout test)", regressionResults: "Spearman=0.453±0.025, Pearson=0.437±0.020", additionalInfo: "Table 3" },
  { id: 37, paper: "DeepDDS (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "DeepDDS-GAT", evaluationStrategy: "5-fold cross-validation", regressionResults: "MAE=0.023±0.001, RMSE=0.041±0.001, Pearson=0.801±0.017", additionalInfo: "Supplementary Table S7" },
  { id: 38, paper: "DeepDDS (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "DeepDDS-GCN", evaluationStrategy: "5-fold cross-validation", regressionResults: "MAE=0.025±0.001, RMSE=0.042±0.001, Pearson=0.797±0.020", additionalInfo: "Supplementary Table S7" },
  { id: 39, paper: "DeepDDS (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "DeepSynergy (baseline)", evaluationStrategy: "5-fold cross-validation", regressionResults: "MAE=0.038±0.001, RMSE=0.053±0.002, Pearson=0.745±0.037", additionalInfo: "Supplementary Table S7" },
  { id: 40, paper: "DeepDDS (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Adaboost (baseline)", evaluationStrategy: "5-fold cross-validation", regressionResults: "MAE=0.041±0.002, RMSE=0.059±0.005, Pearson=0.677±0.044", additionalInfo: "Supplementary Table S7" },
  { id: 41, paper: "DeepDDS (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Random Forest (baseline)", evaluationStrategy: "5-fold cross-validation", regressionResults: "MAE=0.047±0.003, RMSE=0.075±0.011, Pearson=0.638±0.037", additionalInfo: "Supplementary Table S7" },
  { id: 42, paper: "DeepDDS (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "XGBoost (baseline)", evaluationStrategy: "5-fold cross-validation", regressionResults: "MAE=0.066±0.017, RMSE=0.108±0.012, Pearson=0.586±0.033", additionalInfo: "Supplementary Table S7" },
  { id: 43, paper: "DeepDDS (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "MLP (baseline)", evaluationStrategy: "5-fold cross-validation", regressionResults: "MAE=0.129±0.026, RMSE=0.178±0.039, Pearson=0.494±0.045", additionalInfo: "Supplementary Table S7" },
  { id: 44, paper: "DeepDDS (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "SVM (baseline)", evaluationStrategy: "5-fold cross-validation", regressionResults: "MAE=0.183±0.036, RMSE=0.245±0.045, Pearson=0.431±0.076", additionalInfo: "Supplementary Table S7" },
  { id: 45, paper: "MatchMaker (2022)", dataset: "DrugComb - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "MatchMaker", evaluationStrategy: "60% train, 20% validation, 20% test split - 5-fold CV", regressionResults: "MSE=79.49, Pearson=0.79, Spearman=0.74", additionalInfo: "Figure 3 (Results text)" },
  { id: 46, paper: "MatchMaker (2022)", dataset: "DrugComb - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "60% train, 20% validation, 20% test split - 5-fold CV", regressionResults: "MSE=105.9", additionalInfo: "Figure 3 (Results text)" },
  { id: 47, paper: "MatchMaker (2022)", dataset: "DrugComb - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "TreeCombo", evaluationStrategy: "60% train, 20% validation, 20% test split - 5-fold CV", regressionResults: "MSE=132.7", additionalInfo: "Figure 3 (Results text)" },
  { id: 48, paper: "MatchMaker (2022)", dataset: "DrugComb - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "Random Forest", evaluationStrategy: "60% train, 20% validation, 20% test split - 5-fold CV", regressionResults: "MSE=173.2", additionalInfo: "Figure 3 (Results text)" },
  { id: 49, paper: "MatchMaker (2022)", dataset: "DrugComb - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "ElasticNet", evaluationStrategy: "60% train, 20% validation, 20% test split - 5-fold CV", regressionResults: "MSE=183.4", additionalInfo: "Figure 3 (Results text)" },
  { id: 50, paper: "MatchMaker (2022)", dataset: "DrugComb - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "Baseline (predicts average synergy per cell line)", evaluationStrategy: "60% train, 20% validation, 20% test split - 5-fold CV", regressionResults: "MSE=202.5", additionalInfo: "Figure 3 (Results text)" },
  { id: 51, paper: "MatchMaker (2022)", dataset: "O'Neil/Merck - 38 drugs, 30 cell lines (after filtering), 18,346 samples", synergyMetric: "Loewe", model: "MatchMaker", evaluationStrategy: "Not stated; same hyperparameters as above", regressionResults: "MSE=267.9, Pearson=0.69, Spearman=0.69", additionalInfo: "Table 7" },
  { id: 52, paper: "MatchMaker (2022)", dataset: "O'Neil/Merck - 38 drugs, 30 cell lines (after filtering), 18,346 samples", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Not stated; same hyperparameters as above", regressionResults: "MSE=290.0, Pearson=0.66, Spearman=0.67", additionalInfo: "Table 7" },
  { id: 53, paper: "MatchMaker (2022)", dataset: "O'Neil/Merck - 38 drugs, 30 cell lines (after filtering), 18,346 samples", synergyMetric: "Loewe", model: "TreeCombo", evaluationStrategy: "Not stated; same hyperparameters as above", regressionResults: "MSE=283.1, Pearson=0.67, Spearman=0.67", additionalInfo: "Table 7" },
  { id: 54, paper: "MatchMaker (2022)", dataset: "O'Neil/Merck - 38 drugs, 30 cell lines (after filtering), 18,346 samples", synergyMetric: "Loewe", model: "Random Forest", evaluationStrategy: "Not stated; same hyperparameters as above", regressionResults: "MSE=342.4, Pearson=0.57, Spearman=0.58", additionalInfo: "Table 7" },
  { id: 55, paper: "MatchMaker (2022)", dataset: "O'Neil/Merck - 38 drugs, 30 cell lines (after filtering), 18,346 samples", synergyMetric: "Loewe", model: "ElasticNet", evaluationStrategy: "Not stated; same hyperparameters as above", regressionResults: "MSE=305.3, Pearson=0.62, Spearman=0.63", additionalInfo: "Table 7" },
  { id: 56, paper: "PRODeepSyn (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "PRODeepSyn", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=229.49±42.81, RMSE=15.09±1.37, Pearson=0.75±0.02", additionalInfo: "Table 1" },
  { id: 57, paper: "PRODeepSyn (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=255.49, RMSE=15.91±1.56, Pearson=0.73±0.04", additionalInfo: "Table 1" },
  { id: 58, paper: "PRODeepSyn (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "AuDNNSynergy", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=241.12±43.52, RMSE=15.46±1.44, Pearson=0.74±0.03", additionalInfo: "Table 1" },
  { id: 59, paper: "PRODeepSyn (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Elastic Net", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=418.06±53.99, RMSE=20.41±1.30, Pearson=0.45±0.02", additionalInfo: "Table 1" },
  { id: 60, paper: "PRODeepSyn (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "SVR", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=325.91±54.75, RMSE=17.99±1.48, Pearson=0.63±0.02", additionalInfo: "Table 1" },
  { id: 61, paper: "PRODeepSyn (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "Random Forest", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=312.75±41.35, RMSE=17.65±1.13, Pearson=0.64±0.03", additionalInfo: "Table 1" },
  { id: 62, paper: "PRODeepSyn (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,062 samples", synergyMetric: "Loewe", model: "XGBoost", evaluationStrategy: "Leave combination out - 5-fold nested CV", regressionResults: "MSE=296.34±46.37, RMSE=17.16±1.31, Pearson=0.66±0.02", additionalInfo: "Table 1" },
  { id: 63, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "SYNPRED Ensemble", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.35, MSE=18.92, Pearson=0.71, MAE=3.07, Spearman=0.59", additionalInfo: "Supplementary Table 8" },
  { id: 64, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "Extra Trees Classifier/Regressor", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.46, MSE=19.88, Pearson=0.69, MAE=3.14, Spearman=0.58", additionalInfo: "Supplementary Table 8" },
  { id: 65, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "k‑Nearest Neighbors", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=5.71, MSE=32.55, Pearson=0.38", additionalInfo: "Supplementary Table 8" },
  { id: 66, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "Random Forest", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.51, MSE=20.33, Pearson=0.68", additionalInfo: "Supplementary Table 8" },
  { id: 67, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "Support Vector Machine", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=6.90, MSE=47.61, Pearson=0.14", additionalInfo: "Supplementary Table 8" },
  { id: 68, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "XGBoost", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=5.31, MSE=28.22, Pearson=0.53", additionalInfo: "Supplementary Table 8" },
  { id: 69, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "Deep Learning (Architecture 9)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.65, MSE=21.62, Pearson=0.67", additionalInfo: "Supplementary Table 8" },
  { id: 70, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "Deep Learning (Architecture 10)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=5.05, MSE=25.47, Pearson=0.60", additionalInfo: "Supplementary Table 8" },
  { id: 71, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "Deep Learning (Architecture 11)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.73, MSE=22.37, Pearson=0.66", additionalInfo: "Supplementary Table 8" },
  { id: 72, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "Deep Learning (Architecture 12)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.91, MSE=24.07, Pearson=0.64", additionalInfo: "Supplementary Table 8" },
  { id: 73, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Bliss", model: "Deep Learning (Architecture 13)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=5.14, MSE=26.42, Pearson=0.59", additionalInfo: "Supplementary Table 8" },
  { id: 74, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "SYNPRED Ensemble", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.09, MSE=16.70, Pearson=0.73, MAE=2.86, Spearman=0.64", additionalInfo: "Supplementary Table 9" },
  { id: 75, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "Extra Trees Classifier/Regressor", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.28, MSE=18.36, Pearson=0.70, MAE=2.97, Spearman=0.62", additionalInfo: "Supplementary Table 9" },
  { id: 76, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "k‑Nearest Neighbors", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=5.49, MSE=30.11, Pearson=0.41, MAE=3.70", additionalInfo: "Supplementary Table 9" },
  { id: 77, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "Random Forest", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.36, MSE=19.05, Pearson=0.69, MAE=3.03", additionalInfo: "Supplementary Table 9" },
  { id: 78, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "Support Vector Machine", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=6.31, MSE=39.75, Pearson=0.20, MAE=4.38", additionalInfo: "Supplementary Table 9" },
  { id: 79, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "XGBoost", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.86, MSE=23.58, Pearson=0.59, MAE=3.38", additionalInfo: "Supplementary Table 9" },
  { id: 80, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "Deep Learning (Architecture 14)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.41, MSE=19.49, Pearson=0.69, MAE=3.10", additionalInfo: "Supplementary Table 9" },
  { id: 81, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "Deep Learning (Architecture 15)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.77, MSE=22.71, Pearson=0.63, MAE=3.36", additionalInfo: "Supplementary Table 9" },
  { id: 82, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "Deep Learning (Architecture 16)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.53, MSE=20.49, Pearson=0.67, MAE=3.18", additionalInfo: "Supplementary Table 9" },
  { id: 83, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "HSA", model: "Deep Learning (Architecture 17)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.55, MSE=20.66, Pearson=0.67, MAE=3.20", additionalInfo: "Supplementary Table 9" },
  { id: 84, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "SYNPRED Ensemble", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=10.58, MSE=111.92, Pearson=0.71, MAE=6.49, Spearman=0.68", additionalInfo: "Supplementary Table 10" },
  { id: 85, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "Extra Trees Classifier/Regressor", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=10.50, MSE=110.29, Pearson=0.71, MAE=6.76, Spearman=0.68", additionalInfo: "Supplementary Table 10" },
  { id: 86, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "k‑Nearest Neighbors", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=13.56, MSE=183.98, Pearson=0.40, MAE=9.51", additionalInfo: "Supplementary Table 10" },
  { id: 87, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "Random Forest", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=10.58, MSE=111.85, Pearson=0.70, MAE=6.85", additionalInfo: "Supplementary Table 10" },
  { id: 88, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "Support Vector Machine", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=15.07, MSE=227.07, Pearson=0.22, MAE=10.04", additionalInfo: "Supplementary Table 10" },
  { id: 89, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "XGBoost", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.93, MSE=142.21, Pearson=0.60, MAE=8.19", additionalInfo: "Supplementary Table 10" },
  { id: 90, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "Deep Learning (Architecture 5)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.04, MSE=121.87, Pearson=0.68, MAE=6.98", additionalInfo: "Supplementary Table 10" },
  { id: 91, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "Deep Learning (Architecture 6)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.07, MSE=122.59, Pearson=0.68, MAE=6.97", additionalInfo: "Supplementary Table 10" },
  { id: 92, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "Deep Learning (Architecture 7)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.63, MSE=135.31, Pearson=0.64, MAE=7.59", additionalInfo: "Supplementary Table 10" },
  { id: 93, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "Loewe", model: "Deep Learning (Architecture 8)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.45, MSE=131.10, Pearson=0.66, MAE=7.34", additionalInfo: "Supplementary Table 10" },
  { id: 94, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "ZIP", model: "SYNPRED Ensemble", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=3.86, MSE=14.87, Pearson=0.70, MAE=2.74, Spearman=0.66", additionalInfo: "Supplementary Table 11" },
  { id: 95, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "ZIP", model: "Extra Trees Classifier/Regressor", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=3.91, MSE=15.29, Pearson=0.68, MAE=2.78, Spearman=0.65", additionalInfo: "Supplementary Table 11" },
  { id: 96, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "ZIP", model: "k‑Nearest Neighbors", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.72, MSE=22.26, Pearson=0.46, MAE=3.35", additionalInfo: "Supplementary Table 11" },
  { id: 97, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "ZIP", model: "Random Forest", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=3.97, MSE=15.79, Pearson=0.67, MAE=2.83", additionalInfo: "Supplementary Table 11" },
  { id: 98, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "ZIP", model: "Support Vector Machine", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=5.72, MSE=32.75, Pearson=0.24, MAE=4.25", additionalInfo: "Supplementary Table 11" },
  { id: 99, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "ZIP", model: "XGBoost", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.68, MSE=21.92, Pearson=0.48, MAE=3.36", additionalInfo: "Supplementary Table 11" },
  { id: 100, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "ZIP", model: "Deep Learning (Architecture 18)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.20, MSE=17.67, Pearson=0.63, MAE=3.00", additionalInfo: "Supplementary Table 11" },
  { id: 101, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "ZIP", model: "Deep Learning (Architecture 19)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.20, MSE=17.64, Pearson=0.64, MAE=2.98", additionalInfo: "Supplementary Table 11" },
  { id: 102, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "ZIP", model: "Deep Learning (Architecture 20)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=4.37, MSE=19.10, Pearson=0.59, MAE=3.12", additionalInfo: "Supplementary Table 11" },
  { id: 103, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "SYNPRED Ensemble", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.07, MSE=122.61, Pearson=0.86, MAE=7.43, Spearman=0.87", additionalInfo: "Supplementary Table 12" },
  { id: 104, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "Extra Trees Classifier/Regressor", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=10.97, MSE=120.32, Pearson=0.86, MAE=7.79, Spearman=0.87", additionalInfo: "Supplementary Table 12" },
  { id: 105, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "k‑Nearest Neighbors", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=16.45, MSE=270.54, Pearson=0.66, MAE=12.47", additionalInfo: "Supplementary Table 12" },
  { id: 106, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "Random Forest", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.68, MSE=136.45, Pearson=0.84, MAE=8.37", additionalInfo: "Supplementary Table 12" },
  { id: 107, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "Support Vector Machine", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=16.10, MSE=259.23, Pearson=0.68, MAE=12.29", additionalInfo: "Supplementary Table 12" },
  { id: 108, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "XGBoost", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=13.02, MSE=169.51, Pearson=0.80, MAE=9.93", additionalInfo: "Supplementary Table 12" },
  { id: 109, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "Deep Learning (Architecture 21)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.91, MSE=141.74, Pearson=0.84, MAE=8.15", additionalInfo: "Supplementary Table 12" },
  { id: 110, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "Deep Learning (Architecture 22)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.85, MSE=140.45, Pearson=0.84, MAE=8.01", additionalInfo: "Supplementary Table 12" },
  { id: 111, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "Deep Learning (Architecture 23)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=11.88, MSE=141.19, Pearson=0.84, MAE=8.04", additionalInfo: "Supplementary Table 12" },
  { id: 112, paper: "SYNPRED (2022)", dataset: "NCI ALMANAC - 105 drugs, 61 cell lines, 311,466 samples", synergyMetric: "CSS", model: "Deep Learning (Architecture 24)", evaluationStrategy: "80% train, 20% test split", regressionResults: "RMSE=12.19, MSE=148.60, Pearson=0.83, MAE=8.59", additionalInfo: "Supplementary Table 12" },
  { id: 113, paper: "SYNPRED (2022)", dataset: "DrugComb (Matchmaker filtered) - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "SYNPRED Ensemble (Loewe)", evaluationStrategy: "Not explicitly stated", regressionResults: "RMSE=11.11, MSE=123.38, Pearson=0.67, Spearman=0.63", additionalInfo: "Supplementary Table 15" },
  { id: 114, paper: "SYNPRED (2022)", dataset: "DrugComb (Matchmaker filtered) - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "MatchMaker", evaluationStrategy: "Results taken directly from source publication", regressionResults: "MSE=74.49, Pearson=0.79, Spearman=0.74", additionalInfo: "Supplementary Table 15" },
  { id: 115, paper: "SYNPRED (2022)", dataset: "DrugComb (Matchmaker filtered) - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Results taken directly from source publication", regressionResults: "MSE=105.90, Pearson=0.70, Spearman=0.65", additionalInfo: "Supplementary Table 15" },
  { id: 116, paper: "SYNPRED (2022)", dataset: "DrugComb (Matchmaker filtered) - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "TreeCombo", evaluationStrategy: "Results taken directly from source publication", regressionResults: "MSE=13.70, Pearson=0.60, Spearman=0.55", additionalInfo: "Supplementary Table 15" },
  { id: 117, paper: "SYNPRED (2022)", dataset: "DrugComb (Matchmaker filtered) - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "RF", evaluationStrategy: "Results taken directly from source publication", regressionResults: "MSE=173.2, Pearson=0.43, Spearman=0.33", additionalInfo: "Supplementary Table 15" },
  { id: 118, paper: "SYNPRED (2022)", dataset: "DrugComb (Matchmaker filtered) - 3,040 drugs, 81 cell lines, 286,421 samples", synergyMetric: "Loewe", model: "ElasticNet", evaluationStrategy: "Results taken directly from source publication", regressionResults: "MSE=183.4, Pearson=0.37, Spearman=0.31", additionalInfo: "Supplementary Table 15" },
  { id: 119, paper: "Synpathy (2022)", dataset: "DrugComb - 2,287 drugs, 81 cell lines, 157,532 samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Repeated 5-fold CV", regressionResults: "MSE=70.6±6.4", additionalInfo: "Supplementary Table 3" },
  { id: 120, paper: "Synpathy (2022)", dataset: "DrugComb - 2,287 drugs, 81 cell lines, 157,532 samples", synergyMetric: "Loewe", model: "XGBoost", evaluationStrategy: "Repeated 5-fold CV", regressionResults: "MSE=105.1±4.4", additionalInfo: "Supplementary Table 3" },
  { id: 121, paper: "Synpathy (2022)", dataset: "DrugComb - 2,287 drugs, 81 cell lines, 157,532 samples", synergyMetric: "Loewe", model: "ElasticNet", evaluationStrategy: "Repeated 5-fold CV", regressionResults: "MSE=182.7±6.7", additionalInfo: "Supplementary Table 3" },
  { id: 122, paper: "Synpathy (2022)", dataset: "DrugComb - 2,287 drugs, 81 cell lines, 157,532 samples", synergyMetric: "Loewe", model: "SVM", evaluationStrategy: "Repeated 5-fold CV", regressionResults: "MSE=787.1±44.6", additionalInfo: "Supplementary Table 3" },
  { id: 123, paper: "Synpathy (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,052 samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Repeated 5-fold CV", regressionResults: "MSE=64.7±4.2", additionalInfo: "Main paper (Text)" },
  { id: 124, paper: "Synpathy (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,052 samples", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "Results taken directly from source publication", regressionResults: "MSE=255.49", additionalInfo: "Main paper (Text)" },
  { id: 125, paper: "Synpathy (2022)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 23,052 samples", synergyMetric: "Loewe", model: "TranSynergy", evaluationStrategy: "Results taken directly from source publication", regressionResults: "MSE=231±21", additionalInfo: "Main paper (Text)" },
  { id: 126, paper: "Synpathy (2022)", dataset: "DrugComb LOSO - ALMANAC held out - 139,759 training samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Leave-One-Study-Out", regressionResults: "MSE=273.1", additionalInfo: "Table 1" },
  { id: 127, paper: "Synpathy (2022)", dataset: "DrugComb LOSO - O'Neil held out - 12,936 test samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Leave-One-Study-Out", regressionResults: "MSE=279.4", additionalInfo: "Table 1" },
  { id: 128, paper: "Synpathy (2022)", dataset: "DrugComb LOSO - FORCINA held out - 1,423 test samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Leave-One-Study-Out", regressionResults: "MSE=383.6", additionalInfo: "Table 1" },
  { id: 129, paper: "Synpathy (2022)", dataset: "DrugComb LOSO - NCATS-2D-3D held out - 3 test samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Leave-One-Study-Out", regressionResults: "MSE=29.9", additionalInfo: "Table 1" },
  { id: 130, paper: "Synpathy (2022)", dataset: "DrugComb LOSO - NCATS-ESFAKiAURKi held out - 1,441 test samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Leave-One-Study-Out", regressionResults: "MSE=71.0", additionalInfo: "Table 1" },
  { id: 131, paper: "Synpathy (2022)", dataset: "DrugComb LOSO - NCATS-ES-Nampt-PARP held out - 36 test samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Leave-One-Study-Out", regressionResults: "MSE=39.6", additionalInfo: "Table 1" },
  { id: 132, paper: "Synpathy (2022)", dataset: "DrugComb LOSO - NCATS-HL held out - 1,869 test samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Leave-One-Study-Out", regressionResults: "MSE=347.5", additionalInfo: "Table 1" },
  { id: 133, paper: "Synpathy (2022)", dataset: "DrugComb LOSO - Yohe held out - 65 test samples", synergyMetric: "Loewe", model: "Synpathy", evaluationStrategy: "Leave-One-Study-Out", regressionResults: "MSE=91.9", additionalInfo: "Table 1" },
  { id: 134, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "MARSY", evaluationStrategy: "Leave triple out - 5-fold CV", regressionResults: "SCC=0.780±0.010, PCC=0.886±0.005, RMSE=5.36±0.19", additionalInfo: "Table 1" },
  { id: 135, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "MatchMaker", evaluationStrategy: "Leave triple out - 5-fold CV", regressionResults: "SCC=0.742±0.004, PCC=0.873±0.006, RMSE=6.11±0.32", additionalInfo: "Table 1" },
  { id: 136, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "TreeCombo/XGBoost", evaluationStrategy: "Leave triple out - 5-fold CV", regressionResults: "SCC=0.737±0.004, PCC=0.870±0.003, RMSE=5.73±0.17", additionalInfo: "Table 1" },
  { id: 137, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "DeepSynergy", evaluationStrategy: "Leave triple out - 5-fold CV", regressionResults: "SCC=0.701±0.003, PCC=0.869±0.004, RMSE=5.78±0.18", additionalInfo: "Table 1" },
  { id: 138, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "MLP", evaluationStrategy: "Leave triple out - 5-fold CV", regressionResults: "SCC=0.675±0.002, PCC=0.840±0.004, RMSE=6.30±0.15", additionalInfo: "Table 1" },
  { id: 139, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "SVM", evaluationStrategy: "Leave triple out - 5-fold CV", regressionResults: "SCC=0.689±0.004, PCC=0.783±0.006, RMSE=7.65±0.19", additionalInfo: "Table 1" },
  { id: 140, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "Random Forest", evaluationStrategy: "Leave triple out - 5-fold CV", regressionResults: "SCC=0.419±0.003, PCC=0.646±0.016, RMSE=9.16±0.25", additionalInfo: "Table 1" },
  { id: 141, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "LASSO", evaluationStrategy: "Leave triple out - 5-fold CV", regressionResults: "SCC=0.342±0.009, PCC=0.433±0.013, RMSE=10.41±0.21", additionalInfo: "Table 1" },
  { id: 142, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "Elastic Net", evaluationStrategy: "Leave triple out - 5-fold CV", regressionResults: "SCC=0.342±0.009, PCC=0.432±0.012, RMSE=10.42±0.21", additionalInfo: "Table 1" },
  { id: 143, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "MARSY", evaluationStrategy: "Leave pair out - 5-fold CV", regressionResults: "SCC=0.749±0.011, PCC=0.875±0.005, RMSE=5.62±0.15", additionalInfo: "Table 2" },
  { id: 144, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "MatchMaker", evaluationStrategy: "Leave pair out - 5-fold CV", regressionResults: "SCC=0.720±0.006, PCC=0.864±0.007, RMSE=6.23±0.12", additionalInfo: "Table 2" },
  { id: 145, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "TreeCombo/XGBoost", evaluationStrategy: "Leave pair out - 5-fold CV", regressionResults: "SCC=0.689±0.005, PCC=0.856±0.006, RMSE=6.00±0.15", additionalInfo: "Table 2" },
  { id: 146, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "DeepSynergy", evaluationStrategy: "Leave pair out - 5-fold CV", regressionResults: "SCC=0.676±0.006, PCC=0.860±0.008, RMSE=5.95±0.16", additionalInfo: "Table 2" },
  { id: 147, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "MLP", evaluationStrategy: "Leave pair out - 5-fold CV", regressionResults: "SCC=0.642±0.030, PCC=0.822±0.023, RMSE=6.68±0.45", additionalInfo: "Table 2" },
  { id: 148, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "SVM", evaluationStrategy: "Leave pair out - 5-fold CV", regressionResults: "SCC=0.649±0.008, PCC=0.773±0.012, RMSE=7.79±0.14", additionalInfo: "Table 2" },
  { id: 149, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "Random Forest", evaluationStrategy: "Leave pair out - 5-fold CV", regressionResults: "SCC=0.413±0.005, PCC=0.650±0.012, RMSE=9.02±0.17", additionalInfo: "Table 2" },
  { id: 150, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "LASSO", evaluationStrategy: "Leave pair out - 5-fold CV", regressionResults: "SCC=0.333±0.019, PCC=0.430±0.007, RMSE=10.43±0.17", additionalInfo: "Table 2" },
  { id: 151, paper: "MARSY (2023)", dataset: "DrugComb v1.5 - 670 drugs, 2,353 pairs, 75 cell lines, 43,174 triples (86,348 samples)", synergyMetric: "ZIP", model: "Elastic Net", evaluationStrategy: "Leave pair out - 5-fold CV", regressionResults: "SCC=0.333±0.018, PCC=0.429±0.008, RMSE=10.44±0.18", additionalInfo: "Table 2" },
  { id: 152, paper: "El Hafeez et al. (2024)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 22,737 samples", synergyMetric: "CSS (Combination Sensitivity Score)", model: "Linear Regression", evaluationStrategy: "70% train, 30% test split", regressionResults: "MAE=0.102, R²=0.50105, MSE=0.016", additionalInfo: "Figure 7" },
  { id: 153, paper: "El Hafeez et al. (2024)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 22,737 samples", synergyMetric: "CSS (Combination Sensitivity Score)", model: "Ridge Regression", evaluationStrategy: "70% train, 30% test split", regressionResults: "MAE=0.103, R²=0.49399, MSE=0.016", additionalInfo: "Figure 7" },
  { id: 154, paper: "El Hafeez et al. (2024)", dataset: "O'Neil/Merck - 38 drugs, 39 cell lines, 22,737 samples", synergyMetric: "CSS (Combination Sensitivity Score)", model: "Random Forest", evaluationStrategy: "70% train, 30% test split", regressionResults: "MAE=0.09, R²=0.59157, MSE=0.013", additionalInfo: "Figure 7" },
  { id: 155, paper: "MultiComb (2024)", dataset: "O'Neil/Merck - 38 drugs, 37 cell lines, 17,901 samples (35,802 samples order-invariant)", synergyMetric: "Loewe", model: "DeepDDS", evaluationStrategy: "5-fold CV", regressionResults: "MSE=248.20±45.56, RMSE=15.69±1.41, MAE=9.98±0.58, R²=0.54±0.05, Pearson=0.74±0.03, Spearman=0.71±0.02", additionalInfo: "Table 3" },
  { id: 156, paper: "MultiComb (2024)", dataset: "O'Neil/Merck - 38 drugs, 37 cell lines, 17,901 samples (35,802 samples order-invariant)", synergyMetric: "Loewe", model: "DeepDSC", evaluationStrategy: "5-fold CV", regressionResults: "MSE=257.74±41.98, RMSE=16.00±1.28, MAE=10.18±0.56, R²=0.52±0.04, Pearson=0.72±0.03, Spearman=0.71±0.02", additionalInfo: "Table 3" },
  { id: 157, paper: "MultiComb (2024)", dataset: "O'Neil/Merck - 38 drugs, 37 cell lines, 17,901 samples (35,802 samples order-invariant)", synergyMetric: "Loewe", model: "MatchMaker", evaluationStrategy: "5-fold CV", regressionResults: "MSE=254.12±40.60, RMSE=15.93±1.24, MAE=10.12±0.05, R²=0.53±0.03, Pearson=0.73±0.02, Spearman=0.71±0.02", additionalInfo: "Table 3" },
  { id: 158, paper: "MultiComb (2024)", dataset: "O'Neil/Merck - 38 drugs, 37 cell lines, 17,901 samples (35,802 samples order-invariant)", synergyMetric: "Loewe", model: "MultiComb", evaluationStrategy: "5-fold CV", regressionResults: "MSE=232.37±41.24, RMSE=15.19±1.32, MAE=9.59±0.52, R²=0.57±0.04, Pearson=0.76±0.02, Spearman=0.73±0.02", additionalInfo: "Table 3" },
  { id: 159, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "DeepSynergy", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.560", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 160, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "Gemma-2-2B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=8.213", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 161, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "Gemma-2-9B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=7.413", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 162, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "Gemma-2-27B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=6.456", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 163, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "TxGemma-2B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.230", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 164, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "TxGemma-9B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.337", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 165, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "TxGemma-27B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.156", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 166, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "TxGemma-9B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.502", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 167, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "TxGemma-27B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.511", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 168, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "Tx-LLM S (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.425", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 169, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Bliss", model: "Tx-LLM M (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.104", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 170, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "DeepSynergy", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=16.858", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 171, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "Gemma-2-2B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=36.847", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 172, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "Gemma-2-9B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=33.837", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 173, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "Gemma-2-27B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=22.614", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 174, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "TxGemma-2B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=15.752", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 175, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "TxGemma-9B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=16.480", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 176, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "TxGemma-27B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=15.000", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 177, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "TxGemma-9B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=16.384", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 178, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "TxGemma-27B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=16.900", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 179, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "Tx-LLM S (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=14.740", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 180, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "CSS", model: "Tx-LLM M (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=14.057", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 181, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "DeepSynergy", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.453", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 182, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "Gemma-2-2B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=7.458", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 183, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "Gemma-2-9B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=7.365", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 184, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "Gemma-2-27B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=6.670", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 185, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "TxGemma-2B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.231", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 186, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "TxGemma-9B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.335", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 187, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "TxGemma-27B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.209", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 188, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "TxGemma-9B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.497", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 189, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "TxGemma-27B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.520", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 190, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "Tx-LLM S (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.311", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 191, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "HSA", model: "Tx-LLM M (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.118", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 192, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "DeepSynergy", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=9.184", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 193, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "Gemma-2-2B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=13.873", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 194, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "Gemma-2-9B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=13.369", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 195, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "Gemma-2-27B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=14.731", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 196, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "TxGemma-2B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=17.342", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 197, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "TxGemma-9B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=18.665", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 198, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "TxGemma-27B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=17.336", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 199, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "TxGemma-9B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=16.994", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 200, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "TxGemma-27B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=16.914", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 201, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "Tx-LLM S (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=17.428", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 202, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "Loewe", model: "Tx-LLM M (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=17.381", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 203, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "DeepSynergy", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.027", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 204, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "Gemma-2-2B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=8.588", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 205, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "Gemma-2-9B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=6.226", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 206, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "Gemma-2-27B (base model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=5.404", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 207, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "TxGemma-2B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=3.950", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 208, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "TxGemma-9B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=3.904", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 209, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "TxGemma-27B-Predict", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=3.807", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 210, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "TxGemma-9B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.139", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 211, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "TxGemma-27B-Chat", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.141", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 212, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "Tx-LLM S (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=4.047", additionalInfo: "Supplementary Table 14 and 16" },
  { id: 213, paper: "TxGemma (2025)", dataset: "DrugComb (NCI-ALMANAC) - 129 drugs, 59 cell lines, 297,098 samples", synergyMetric: "ZIP", model: "Tx-LLM M (previous model)", evaluationStrategy: "70% train, 10% validation, 20% test split", regressionResults: "MAE=3.777", additionalInfo: "Supplementary Table 14 and 16" }
];
